Graypoint LLC lessened its stake in shares of Royalty Pharma plc (NASDAQ:RPRX – Get Rating) by 47.6% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 43,975 shares of the biopharmaceutical company’s stock after selling 40,026 shares during the period. Graypoint LLC’s holdings in Royalty Pharma were […]
Versor Investments LP boosted its position in Royalty Pharma plc (NASDAQ:RPRX – Get Rating) by 69.9% during the fourth quarter, Holdings Channel.com reports. The fund owned 32,790 shares of the biopharmaceutical company’s stock after purchasing an additional 13,490 shares during the quarter. Versor Investments LP’s holdings in Royalty Pharma were worth $1,296,000 at the end […]
Royalty Pharma (NASDAQ:RPRX – Get Rating) had its price target increased by Tigress Financial from $57.00 to $60.00 in a report published on Thursday, The Fly reports. RPRX has been the subject of several other research reports. StockNews.com began coverage on shares of Royalty Pharma in a research report on Thursday, March 16th. They set […]
Eastern Bank acquired a new position in Royalty Pharma plc (NASDAQ:RPRX – Get Rating) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 233,299 shares of the biopharmaceutical company’s stock, valued at approximately $9,220,000. Several other institutional investors and hedge funds also recently bought and […]
Royalty Pharma plc (NASDAQ:RPRX – Get Rating)’s share price gapped up prior to trading on Monday . The stock had previously closed at $35.43, but opened at $37.50. Royalty Pharma shares last traded at $36.99, with a volume of 778,845 shares changing hands. Analyst Upgrades and Downgrades A number of research analysts have issued reports […]